PHAR

Pharming GroupB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The constructive view is that Joenja is still growing meaningfully despite a messy quarter elsewhere: 1Q26 Joenja revenue rose 34% year over year to $14.1 million, guidance of $405-$425 million was reaffirmed, Japan approval is in hand, EU approval is nearing, and 2H26 PID/CVID readouts offer non-APDS expansion upside [#PR-2026-05-07] [#PR-2026-02-03].

Posture

Constructive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.2.

What can break

Broader leniolisib PID/CVID expansion is still clinical-stage and could fail to replicate APDS efficacy or regulatory tractability.

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $14.00 · Bull $20.00 · Bear $9.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net —

Target $32.69

Why

Momentum65 · Δ7d -

Value64 · Δ7d +0.2

Sentiment50 · Δ7d -

So what

Strength-led posture. Favor watchlist adds and disciplined entries.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.2

Δ21d

-2.6

Sentiment

34% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade B. Momentum 64.5 / Value 63.8 / Sentiment 49.9

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$954.18M

Beta

-0.24

Shares Out

70.78M

P/E (TTM)

411.2

P/S (TTM)

3.16

P/FCF (TTM)

21.75

Rev YoY

-8.1%

EPS YoY

-65.6%

Gross Margin

+87.3%

Op Margin

+7.3%

Net Debt

-$64.09M

Current Ratio

2.63

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology